Johnson & Johnson Covid-19 vaccine batch fails quality check


PTI, Apr 1, 2021, 11:29 AM IST

Image for representation

Washington: A batch of Johnson and Johnson’s Covid-19 vaccine failed quality standards and can’t be used, the drug giant has said.

The drugmaker didn’t say how many doses were lost, and it wasn’t clear how the problem would impact future deliveries.

A vaccine ingredient made by Emergent BioSolutions — one of about 10 companies that Johnson and Johnson is using to speed up manufacturing of its recently approved vaccine — did not meet quality standards, J&J said on Wednesday.

J&J said the Emergent BioSolutions factory involved had not yet been approved by the US Food and Drug Administration to make part of the vaccine. Emergent declined to comment.

J&J had pledged to provide 20 million doses of its vaccine to the US government by the end of March, and 80 million more doses by the end of May. Its statement on the manufacturing problem said it was still planning to deliver 100 million doses by the end of June and was “aiming to deliver those doses by the end of May”.

President Joe Biden has pledged to have enough vaccines for all US adults by the end of May. The US government has ordered enough two-dose shots from Pfizer and Moderna to vaccinate 200 million people to be delivered by late May, plus the 100 million shots from J&J.

A federal official said Wednesday evening the administration’s goal can be met without additional J&J doses.

A J&J spokesperson said earlier Wednesday that the company met the end-of-March goal, but did not respond to questions about whether the Emergent plant in Baltimore, known as Bayview, had been cleared by FDA.

As of Wednesday, J&J had provided about 6.8 million doses to the US vaccine effort, according to the Centers for Disease Control and Prevention’s online vaccine tracker.

Some additional doses may not yet have been recorded as delivered, and federal health officials said Wednesday that another 11 million doses of the vaccine would be available for shipments starting on Thursday.

It was not immediately clear where those 11 million doses originated, but J&J has been shipping finished vaccines from its factory in the Netherlands to the US.

Emergent, a little known pharmaceutical company granted a major role in the federal government’s response to coronavirus pandemic, has been repeatedly cited by the FDA for problems ranging from poorly trained employees to cracked vials and mold around one of its facilities, according to records obtained by The Associated Press through the Freedom of Information Act.

The records cover inspections at Emergent facilities, including Bayview, since 2017. Following a December 2017 inspection at an Emergent plant in Canton, Massachusetts, the FDA said the company hadn’t corrected “continued low level mold and yeast isolates” found in the facility.

Nearly a year later, agency investigators questioned why Emergent had “an unwritten policy of not conducting routine compliance audits” at a separate plant in Baltimore, known as Camden, where an anthrax vaccine is filled into vials.

Emergent’s revenues skyrocketed during the Trump administration, jumping from around $523 million in 2015 to more than $1.5 billion in 2020. The company has invested heavily in lobbying the federal government, according to disclosure records, which show the company spent $3.6 million on lobbying in 2020 alone.

J&J said it was putting more of its manufacturing and quality experts inside Emergent’s factory to supervise production of the Covid-19 vaccine, a move meant to enable delivery of an additional 24 million vaccine doses through April.

J&J said it still expects to deliver more than 1 billion vaccine doses globally by the end of the year.

The J&J vaccine has been viewed as crucial for vaccination campaigns around the world, because only one shot is required and it can be shipped and stored at standard refrigeration temperatures, unlike some other vials that must be kept frozen. The company also has pledged to sell the vaccine without a profit, but only during the pandemic emergency.

The problem with the vaccine batch was first reported by The New York Times. The FDA said it was aware of the situation but declined further comment.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Seven assembly bypolls in six states on Nov 3: EC

Former Goa minister Pandurang Raut passes away

Randeep Hooda begins filming Savarkar biopic

BJP accuses DMK legislator of demanding kickback

Sonia Gandhi to arrive in Mysuru today; to visit Chamundeshwari hills along with Rahul

‘Bomb scare’: IAF fighter jets dispatched to intercept Iranian plane

Engine failure delays Bengaluru-Kannur train


Related Articles More

India condemns hate crime at Shri Bhagavad Gita Park in Canada, urges prompt action against perpetrators

Turkey says 23 Kurdish militants killed in Iraq airstrikes

Mahatma Gandhi makes special appearance at UN, shares message on education

129 dead after fans stampede to exit Indonesian soccer match

1984 marks one of ‘darkest’ years in modern Indian history: US senator

MUST WATCH

Day 8 | Mahagauri

Sarapady Devadas Special Video.

Day 7 | Goddess Kalratri

Huge Fish Found in Muloor

Uchila Dasara 2022 Celebration


Latest Additions

Puducherry electricity dept staff detained for protesting against privatization plans

Kota: 30 students fall sick after eating contaminated hostel food; probe ordered

Netizens seek action against organisers of Durga Puja that had Asura looking like Gandhi

Seven assembly bypolls in six states on Nov 3: EC

Appointment on compassionate ground concession not a right: SC

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.